
Musey addressed any gaps and limitations that researchers should be focusing on in future studies and what he hopes to see for the future of pneumococcal vaccines and this disease.

Musey addressed any gaps and limitations that researchers should be focusing on in future studies and what he hopes to see for the future of pneumococcal vaccines and this disease.

The mechanism of action of solriamfetol is mediated through its activity as a dopamine and norepinephrine reuptake inhibitor indicated for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.

In its most severe form, Guillain-Barre syndrome is a medical emergency.

Washington State University study results show that slumber-deprived individuals had more difficulty reducing the emotions they felt when so instructed than those who slept normally.

A phase 3 trial met the primary endpoint, and the long-acting antibody combination reduced symptoms or death by 67% for patients compared with those who took a placebo.

Abemaciclib (Verzenio) approved in combination with endocrine therapy for the adjuvant treatment of adult patients with HR–positive, HER2-negative, node-positive, early breast cancer at high risk of recurrence.

A clear gastrointestinal tract promotes a healthy body and mind and keeps the immune system robust.

National Community Pharmacists Association (NCPA) President Brian Caswell, RPh, said he is incredibly proud of the work community pharmacists have done over the past year.


Adults 40 to 59 years of age should consult their clinician before taking aspirin, and adults 60 years of age and older should stop aspirin use for the prevention of cardiovascular disease.

Michael Frank, CEO of Revive Therapeutics, and Derrick Welsh, COO of Psilocin Pharma, a division of Revive Therapeutics, discuss clinical research investigating novel treatment targets for psilocybin, such as treatment-resistant depression in patients with cancer.

Pharmacy Times spoke with Dr. Jeffrey Akers, CEO of Pharmaceutical Services at Appalachian Regional Healthcare, about how integrated technology can empower pharmacists to prioritize patient care and safety and can help prevent harmful medication events from occurring.

Although October has long been celebrated as National Pharmacy Month, it is only in recent years that female pharmacists have been celebrated for their contributions to the profession and patient care.

The authors said stigmatization threatens societal cohesion during times of national upheaval, such as during a pandemic.

Jameshia Below, PharmD, assistant professor of pharmacy practice at the University of Louisiana Monroe College of Pharmacy, explains how oncologic emergencies present in patients, and how each type can be recognized.

October 12 observance gives special recognition to the significant achievements made.

Patients receiving sacituzumab govitecan also reported lower symptomatic impact of fatigue, pain, dyspnea, and insomnia.

Biotin deficiency can cause thinning of the hair and a rash on the face.

Evolocumab is a PCSK9 inhibitor indicated to reduce the risk of myocardial infarction, stroke, and coronary revascularization in adults with established cardiovascular disease.

People who inherit familial hypercholesterolemia from both parents usually develop symptoms in childhood.

Fluciclovine F 18 (Axumin), which is a radioactive diagnostic agent for injection that can be used to detect recurring prostate cancer.

AbbVie announced positive top-line results from a phase 3 trial for the efficacy and safety of upadacitinib for individuals with the rheumatic disease.

The PROpel phase 3 trial met the primary endpoints of radiographic progressing-free for men with metastatic castration-resistant prostate when treated with Olaparib, combined with abiraterone.

The medication, which has been cleared as a treatment for the inflammatory disease of the throat, is under priority review by the agency.

There are 3 PARP inhibitors that are FDA approved in multiple settings of ovarian cancer.

The study aimed to examine the impact of masking and social distancing practices used to control the spread of COVID-19.

The majority of treatment-related adverse events (TRAEs) were grade 1-2 in severity, and no patients experienced dose-limiting toxicities during the 28 days following initial treatment.

The researchers used a body composition analysis of patients with Crohn disease in a collaboration with gastroenterology and surgical specialists.

The study also failed to meet its secondary efficacy endpoints and no new safety signals were observed.

Allostatic load is caused by a number of different stressors, including social isolation, poverty, and racism, many of which are commonly experienced by individuals belonging to racial and ethnic minorities, according to the investigators.